Navitas Life Sciences

MEDICAL WRITING

A European company, a large global leader in medical imaging contrast media, wanted to understand the efficacy and safety of one of its imaging contrast agents that was being used across the globe to visualize, through Computed Tomography (CT), lesions in the livers of adults with known or suspected Hepatocellular Carcinoma (HCC).

An integrated summary of efficacy and integrated summary of safety (ISS) report was created based on a literature study of published data from studies using the contrast agent as per the recommended protocol.

Learn how Navitas Life Sciences domain expertise accelerated the study.

 

Please complete form to download PDF
First Name
Last Name
Business Email
Company
Job Title
Country
By submitting this form, I agree to receive email communications from Navitas Life Sciences. View Navitas Life Sciences' Privacy Policy

© 2018 Navitas Life Sciences | A TAKE Solutions Enterprise  | privacy policy